MBVax Bioscience Revives Century-Old 'Coley's Toxins' Cancer Therapy

MBVax Bioscience Revives Century-Old 'Coley's Toxins' Cancer Therapy

October 02, 2006

    ANCASTER, Ontario, Oct. 3 /Xinhua-PRNewswire/ -- MBVax
Bioscience ( http://www.mbvax.com ), a biopharmaceutical
company, announced today the availability of Coley Fluid
(Coley's Toxins) for authorized clinical trials and MB
Fluid for immunology research.

    Coley Fluid, developed by William Coley in 1893, was a
mainstream cancer therapy for 60 years. Since the advent of
chemotherapy in the 1950s, there have been improvements in
5-year cancer survival, but mortality rates have remained
virtually unchanged ( http://www.seer.cancer.gov ). High
cancer mortality rates have generated new interest in Coley
Fluid because it was effective against advanced cancer. More
than 100 scientific publications describe cases of advanced
cancers including breast, colon, kidney, liver, sarcomas,
lymphomas, myelomas and leukemias that were successfully
treated with Coley Fluid. 

    MBVax Coley Fluid is equivalent to the historical
preparation responsible for the largest number of
successful treatments. For authorized clinical trials, the
company will supply Coley Fluid and a complete set of
clinical trial documentation without charge.

    MB Fluid is equivalent to the best historical
preparation used in animal models of cancer and for in
vitro research. MB Fluid is not suitable for human use. MB
Fluid will be of particular interest to researchers
studying the innate immune system. 

    About MBVax Bioscience

    MBVax Bioscience is a biopharmaceutical company with
proprietary technology for manufacturing complex biological
products such as Coley Fluid and MB Fluid.

    For more information, please contact:

     Don MacAdam
     Tel:   [phone]
     Email: [e-mail] 

SOURCE  MBVax Bioscience